Search results for "pharmacology [Excitatory Amino Acid Antagonists]"

showing 10 items of 421 documents

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain.

2020

ObjectiveObservations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.Research design and methodsDeidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were desc…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypoglycemialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusmedicineHumans030212 general & internal medicine1506GlycemicBlood glucose monitoringmedicine.diagnostic_testbusiness.industryBlood Glucose Self-MonitoringEmerging Technologies Pharmacology and Therapeuticsmedicine.diseaseDiabetes Mellitus Type 1GlucosehypoglycemiaSpainCardiologyglycemic controlblood glucose monitoringbusinessReal world dataBMJ open diabetes researchcare
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Impact of orphan drugs on Latvian budget

2016

Background Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. Methods Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total pharmaceuti…

Budgetsendocrine systemOrphan Drug ProductionCost-Benefit AnalysisPharmacology toxicologyPharmacologyOrphan drug03 medical and health sciences0302 clinical medicineOrphan Drug ProductionOrphan drugsHumansEnzyme Replacement TherapyGenetics(clinical)Pharmacology (medical)030212 general & internal medicinehealth care economics and organizationsGenetics (clinical)ReimbursementMucopolysaccharidosis IIMedicine(all)Public economicsCost–benefit analysisResearch030503 health policy & servicesExpenditureLatvianGeneral MedicineBudget impactLatviaReimbursementlanguage.human_languageBudget impactlanguageBusiness0305 other medical scienceRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of pati…

2000

NY-ESO-1 is a member of the cancer-testis family of tumor antigens that elicits strong humoral and cellular immune responses in patients with NY-ESO-1–expressing cancers. Since CD4+ T lymphocytes play a critical role in generating antigen-specific cytotoxic T lymphocyte and antibody responses, we searched for NY-ESO-1 epitopes presented by histocompatibility leukocyte antigen (HLA) class II molecules. Autologous monocyte-derived dendritic cells of cancer patients were incubated with recombinant NY-ESO-1 protein and used in enzyme-linked immunospot (ELISPOT) assays to detect NY-ESO-1–specific CD4+ T lymphocyte responses. To identify possible epitopes presented by distinct HLA class II allele…

CD4-Positive T-LymphocytesImmunologyMolecular Sequence DataAntigen-Presenting Cells10050 Institute of Pharmacology and Toxicology610 Medicine & healthHuman leukocyte antigenBiologyEpitopeCell LineAntigenAntigens NeoplasmImmunology and AllergyCytotoxic T cellHumansAmino Acid SequenceAntigen-presenting cellMelanomaHLA-DRB4Alleles2403 ImmunologyHLA class II–restricted NY-ESO-1 epitopesMembrane ProteinsProteinsT lymphocyteDendritic CellsHLA-DR AntigensVirologyRecombinant ProteinsHistocompatibilityImmunologyCD4+ T cell recognition2723 Immunology and Allergy570 Life sciences; biologyOriginal ArticleHLA-DRB4 Chains
researchProduct

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

1996

Antigenic peptides derived from several differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs). To examine their potential role in tumour-directed immune responses in vivo, we determined CTL reactivity against seven antigenic peptides derived from the Melan A/MART-1, tyrosinase and gp100/Pmel17 antigens in the peripheral blood of 10 HLA-A2+ healthy controls and 26 HLA-A2+ melanoma patients. The influenza matrix peptide (GILGFVFTL) presented by HLA-A2.1 was used as a control peptide. CTL reactivity was assessed in a mixed lymphocyte 'peptide' culture assay. Reactivity against Melan A/MAR…

Cancer ResearchLymphocyte10050 Institute of Pharmacology and Toxicology610 Medicine & healthDermatologyPeripheral blood mononuclear cell2708 DermatologyMART-1 AntigenImmune systemMelanocyte differentiationAntigenAntigens NeoplasmTumor Cells CulturedmedicineHumansCytotoxic T cell1306 Cancer ResearchAmino Acid SequenceMelanomaneoplasmsMembrane GlycoproteinsMonophenol Monooxygenasebusiness.industryMelanomaProteinsmedicine.diseaseAntigens DifferentiationNeoplasm ProteinsCTL*medicine.anatomical_structureOncologyImmunology570 Life sciences; biology2730 OncologybusinessT-Lymphocytes Cytotoxicgp100 Melanoma AntigenMelanoma Research
researchProduct

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

2010

We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS) comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the top association signals in 15,694 cases, 14,026 controls and 414 parent-offspring trios. We identified 30 new susceptibility loci meeting genome-wide significance (P < 5 x 10(-8)). A series of in silico analyses highlighted particular genes within these loci and, together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP. Combined with previously confirmed loci, these results identify 71 distinct loci with gen…

Candidate geneGenetic LinkagePROTEINGenome-wide association studyInflammatory bowel diseaseGenomeACTIVATION0302 clinical medicineCrohn DiseaseSEQUENCE VARIANTSGenetics0303 health sciencesGenomeNEDD4 FAMILYCOMMON VARIANTSASSOCIATION3. Good health030220 oncology & carcinogenesis10076 Center for Integrative Human PhysiologyComputational Biology; Crohn Disease; Genetic Linkage; Genetic Loci; Genetic Variation; Genome Human; Humans; Reproducibility of Results; Genetic Predisposition to Disease; Genome-Wide Association Study; Geneticsinflammatory-bowel-disease sequence variants common variants nedd4 family association gene identification receptor protein activationHuman/dk/atira/pure/subjectarea/asjc/1300/1311Locus (genetics)610 Medicine & healthBiology03 medical and health sciences1311 GeneticsGenetic linkagemedicineGeneticsHumansGenetic Predisposition to Disease030304 developmental biologyGenetic associationIDENTIFICATIONRECEPTORComputational BiologyGenetic VariationReproducibility of Resultsmedicine.diseaseGENESettore MED/03 - Genetica Medica10199 Clinic for Clinical Pharmacology and ToxicologyGenetic Loci570 Life sciences; biologyHuman genomegenome-wide scan.meta-analysis.crohn's diseaseGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASE
researchProduct

Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.

2011

Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in t…

Cardiovascular toxicityTime FactorsSettore MED/06 - Oncologia MedicaPharmacology toxicologyCardiologyAntineoplastic AgentsPharmacologyToxicologyMedical OncologyCardiotoxinsCardiovascular SystemProfessional RolePharmacovigilanceMedicineAnimalsHumansPhysician's RoleMolecular BiologyPharmacologyCardiotoxicitybusiness.industryCardiovascular toxicity Anthracyclines Tyrosine kinase inhibitors TrastuzumabSettore MED/11 - Malattie Dell'Apparato CardiovascolareAnticancer drugLaboratory PersonnelCardiovascular DiseasesSettore BIO/14 - FarmacologiaCardiology and Cardiovascular MedicinebusinessOncology drugsCardiovascular toxicology
researchProduct

The isolated perfused rat brain as a model for studying drugs acting on the CNS

1974

An isolated perfused brain preparation is regarded as offering some important advantages over intact animals or tissue slices for studying drug effects on the CNS. The rat is by far the most suitable laboratory animal for this technique because of low cost, ease of preparation and extensive literature available for comparative purposes. In this paper various preparation techniques and perfusion systems for an isolated rat brain are reported. Investigations are presented proving the viability of the isolated perfused rat brain for more than seven hours and its suitability for studies on cerebral metabolism. Until now this preparation has been successfully used for pharmacological investigati…

Central Nervous SystemDrugmedia_common.quotation_subjectCentral nervous systemPharmacology toxicologyDrug Evaluation PreclinicalEnergy metabolismCerebral metabolismIn Vitro TechniquesBiologyPharmacologyOxygen ConsumptionPharmacokineticsMethodsmedicineAnimalsmedia_commonPharmacologyBrainElectroencephalographyRat brainRatsPerfusionmedicine.anatomical_structurePerfusionNeurosciencePsychopharmacologia
researchProduct

Characterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system.

2013

Abstract Background The vesicular B0AT3 transporter (SLC6A17), one of the members of the SLC6 family, is a transporter for neutral amino acids and is exclusively expressed in brain. Here we provide a comprehensive expression profile of B0AT3 in mouse brain using in situ hybridization and immunohistochemistry. Results We confirmed previous expression data from rat brain and used a novel custom made antibody to obtain detailed co-labelling with several cell type specific markers. B0AT3 was highly expressed in both inhibitory and excitatory neurons. The B0AT3 expression was highly overlapping with those of vesicular glutamate transporter 2 (VGLUT2) and vesicular glutamate transporter 1 (VGLUT1…

Central Nervous SystemMaleSerotonin reuptake inhibitorVesicular glutamate transporter 1Central nervous systemVesicular Transport ProteinsNerve Tissue ProteinsIn situ hybridizationPharmacology and ToxicologyPharmacologyBiologyPlasma Membrane Neurotransmitter Transport ProteinsRats Sprague-DawleyCellular and Molecular NeuroscienceGlutamatergicMiceDopaminePregnancyMonoaminergicmedicineAnimalsRats WistarCells CulturedNeuronsGeneral NeuroscienceNeurosciencesTransporterFarmakologi och toxikologiEmbryo MammalianAntidepressive AgentsRatsMice Inbred C57BLProtein Transportmedicine.anatomical_structureGene Expression Regulationbiology.proteinFemaleFood DeprivationNeurovetenskapermedicine.drugResearch ArticleBMC neuroscience
researchProduct

Comparison of the effects of chloral hydrate and trichlorethanol on the EEG of the isolated perfused rat brain.

1973

An isolated perfused rat brain preparation was used to compare the effects of chloral hydrate and its metabolite trichloroethanol on the EEG. The concentrations of chloral hydrate and trichloroethanol in the perfusion medium ranged from 1.5 to 5.5 mM. 5, 10, 15, and 30 min after the beginning of the perfusions EEG-recordings were taken. The recordings were evaluated both by a descriptive method and by a simple quantitative appraoch, counting the waves with an amplitude greater than 50 microvolts and averaging this value for a period of 1 sec. The following results were obtained: Both drugs exhibited CNS depressant activity. Between 5 and 10 min of perfusion the effect of trichloroethanol wa…

Central Nervous SystemMaleTime FactorsMetaboliteCns depressantPharmacology toxicologyChloral hydrateElectroencephalographyIn Vitro Techniqueschemistry.chemical_compoundmedicineAnimalsChloral HydratePharmacologymedicine.diagnostic_testEthanolChemistryHydrocarbons HalogenatedBrainElectroencephalographyGeneral MedicineRat brainRatsPerfusionAnesthesiaChlorinePerfusionmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct